Axon Enterprise (NASDAQ:AXON) Stock Price Up 6.4% – Here’s Why

Axon Enterprise, Inc (NASDAQ:AXON)’s stock price shot up 6.4% on Wednesday . The stock traded as high as $467.97 and last traded at $470.4250. 1,463,181 shares changed hands during mid-day trading, an increase of 39% from the average session volume of 1,050,970 shares. The stock had previously closed at $442.08.

Key Headlines Impacting Axon Enterprise

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Axon’s $1 billion financing carries a 0% coupon and gives the company substantial capital to invest in growth, products and acquisitions without immediate cash interest expense. Analysts remain broadly constructive, with the consensus rating described as “Moderate Buy.” Axon Announces Pricing of $1.0 Billion Offering of 0% Convertible Senior Notes Due 2031
• Positive Sentiment: A temporary advance in Axon stock occurred on above-average volume, with recent earnings-estimate revisions potentially supporting the company’s near-term outlook. Axon’s latest reported quarter also showed strong revenue growth, although valuation remains demanding. Strength Seen in Axon
• Neutral Sentiment: The convertible notes mature in 2031, and underwriters can purchase an additional $150 million. The long-dated, zero-coupon structure limits near-term interest costs, but the eventual conversion terms create uncertainty around future share issuance. What’s Going On With Axon Shares on Wednesday?
• Negative Sentiment: Investors reacted negatively to the financing because convertible notes can dilute existing shareholders and raised questions about Axon’s cash-flow needs. Reports characterized the offering as the main catalyst for the selloff, causing the stock to underperform the broader market. Axon Enterprise Is Down After Convertible Notes Offering
• Negative Sentiment: Separate coverage cited insider selling and Axon’s elevated valuation as additional pressure points. With a high earnings multiple and a thin margin of safety, investors may be less tolerant of financing-related dilution or weaker cash-flow trends. Axon Shares Gap Down After Insider Selling

Analyst Upgrades and Downgrades

AXON has been the subject of several research reports. Argus upped their price objective on shares of Axon Enterprise from $460.00 to $600.00 and gave the stock a “buy” rating in a report on Thursday, September 3rd. Zacks Research cut shares of Axon Enterprise from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 10th. Needham & Company LLC reaffirmed a “buy” rating on shares of Axon Enterprise in a research note on Wednesday, September 2nd. Weiss Ratings reiterated a “hold (c-)” rating on shares of Axon Enterprise in a research report on Wednesday, August 5th. Finally, Citizens Jmp reissued a “market outperform” rating and issued a $700.00 price target on shares of Axon Enterprise in a research note on Thursday, June 25th. Fourteen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, Axon Enterprise has a consensus rating of “Moderate Buy” and an average target price of $721.57.

Axon Enterprise Stock Down 3.2%

The company has a quick ratio of 1.80, a current ratio of 2.15 and a debt-to-equity ratio of 0.47. The stock has a market capitalization of $36.84 billion, a PE ratio of 188.18, a price-to-earnings-growth ratio of 8.82 and a beta of 1.40. The company’s fifty day moving average price is $549.86 and its 200-day moving average price is $487.40.

Axon Enterprise (NASDAQ:AXON) last released its earnings results on Wednesday, August 5th. The biotechnology company reported $1.88 EPS for the quarter, topping analysts’ consensus estimates of $1.84 by $0.04. Axon Enterprise had a return on equity of 2.84% and a net margin of 6.19%.The firm had revenue of $904.39 million for the quarter, compared to analysts’ expectations of $876.42 million. During the same period in the prior year, the firm posted $2.12 earnings per share. The company’s quarterly revenue was up 35.3% on a year-over-year basis. Analysts forecast that Axon Enterprise, Inc will post 2.12 earnings per share for the current year.

Insiders Place Their Bets

In other Axon Enterprise news, insider Isaiah Fields sold 1,017 shares of the business’s stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $480.45, for a total value of $488,617.65. Following the completion of the transaction, the insider owned 56,264 shares of the company’s stock, valued at approximately $27,032,038.80. The trade was a 1.78% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President Joshua Isner sold 16,775 shares of the company’s stock in a transaction dated Monday, August 31st. The shares were sold at an average price of $574.43, for a total transaction of $9,636,063.25. Following the transaction, the president owned 296,974 shares in the company, valued at $170,590,774.82. This represents a 5.35% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 67,397 shares of company stock valued at $38,160,884 over the last quarter. Corporate insiders own 4.20% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bouchey Financial Group Ltd. purchased a new stake in Axon Enterprise in the second quarter worth approximately $215,000. The Manufacturers Life Insurance Company lifted its holdings in shares of Axon Enterprise by 8,432.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,537,957 shares of the biotechnology company’s stock valued at $1,983,414,000 after buying an additional 3,496,493 shares during the period. Barbara Oil Co. lifted its holdings in shares of Axon Enterprise by 100.0% during the 2nd quarter. Barbara Oil Co. now owns 3,390 shares of the biotechnology company’s stock valued at $2,046,000 after buying an additional 1,695 shares during the period. Sequoia Financial Advisors LLC boosted its stake in shares of Axon Enterprise by 1.4% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 4,443 shares of the biotechnology company’s stock worth $2,491,000 after buying an additional 63 shares during the last quarter. Finally, National Pension Service grew its holdings in shares of Axon Enterprise by 18.4% in the second quarter. National Pension Service now owns 118,234 shares of the biotechnology company’s stock worth $66,283,000 after acquiring an additional 18,398 shares during the period. Institutional investors own 79.08% of the company’s stock.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and equipment for law enforcement, public safety and other government agencies. Its product portfolio includes TASER energy weapons, body-worn cameras, in-car cameras and related connected devices designed to support safer interactions, improve transparency and collect operational data.

The company also provides cloud-based software for managing digital evidence, conducting investigations, overseeing records and workflows, coordinating dispatch and supporting real-time public safety operations.